## Review setup
- **Input scope** Full manuscript text (review article, no supplementary materials provided)
- **Assessment boundary** Scientific content, structural logic, evidence quality, and clarity of the review as presented in the main text and figures referenced
- **Shared manuscript claim summary** The authors review recent literature on RPA phosphorylation in DNA double-strand break repair, focusing on structural analysis, DNA and protein interactions, and the role of post-translational modifications, concluding that RPA phosphorylation is complex and under-characterized, with future research directions proposed.
- **Visible evidence base** Main text sections 1-7, Figure 1 (structure schematic and AlphaFold model), Figure 2 (capillary IEF data), Figure 3 (summary of phosphorylation sites), Table 1 (AlphaFold predictions), Table 2 (RPA interaction partners)
- **Missing materials affecting confidence** Supplementary figures, detailed methods for AlphaFold modeling, raw IEF data, full reference list, and any experimental validation data are not provided. Figure 2 and Figure 3 are referenced but not fully described in the text.

## Reviewer
- **Overall assessment** This review addresses a timely and important topic, namely the role of RPA phosphorylation in DNA double-strand break repair. The authors bring together a wide range of literature and present a useful summary of structural and functional aspects of RPA. However, the manuscript suffers from a lack of critical synthesis, overstatement of certain claims without direct evidence, and a somewhat disorganized structure that weakens its impact. The review is more descriptive than analytical, and several key claims are not adequately supported by the cited literature or the data presented. The potential readership is broad, but the current form does not fully meet the standards of a high-impact review.
- **Who would be interested in the results, and why** Researchers in DNA repair, genome stability, cell cycle regulation, and cancer biology would find this review relevant. The focus on RPA phosphorylation and its role in DSB repair is of interest to those studying homologous recombination, RAD51-mediated repair, and therapeutic targeting of DNA repair pathways in cancer. Structural biologists studying flexible proteins and PTM regulation may also find the structural discussion useful.
- **Major strengths** The review covers a broad range of recent literature and integrates structural, biochemical, and cellular perspectives. The use of AlphaFold modeling to visualize phosphorylation sites is a novel and potentially useful contribution. The discussion of future research directions, particularly the therapeutic targeting of phosphoRPA complexes, is forward-looking and relevant.
- **Major Concerns** The review lacks a clear thesis and critical evaluation of conflicting or incomplete data. Several claims are made without direct citation or with citations that do not clearly support the statement. The structural section is overly reliant on a single AlphaFold model without discussion of its limitations. The functional significance of specific phosphorylation sites is often speculated rather than grounded in experimental evidence. The organization is somewhat repetitive, with topics revisited across sections without clear progression.
- **Minor Comments** The abstract is overly general and does not clearly state the main conclusions or novel insights. The introduction is lengthy and includes historical details that are not essential. Some figures are referenced but not adequately explained in the text. The use of terms such as "intriguing mystery" is informal and not appropriate for a scientific review. The reference list is extensive but not critically evaluated.
- **Technical failings that need to be addressed before the case is established** The review does not provide a systematic comparison of phosphorylation sites across studies, nor does it address the functional redundancy or specificity of these sites. The claim that "RPA is always a phosphoprotein in the G2 phase" is based on a single study and is presented as a general fact. The AlphaFold model is presented as a reliable representation of the full-length protein without acknowledging its predictive nature or the variability of disordered regions.
- **Assessment against Nature-style criteria** Originality: The topic is not new, and the review does not offer a novel framework or hypothesis. Scientific importance: The topic is important, but the review does not elevate the discussion beyond existing summaries. Interdisciplinary readership: The review may appeal to a niche audience but is not written to engage a broader scientific community. Technical soundness: The review is generally accurate but lacks critical depth and does not address methodological limitations. Readability for nonspecialists: The text is accessible but includes jargon and lacks clear explanations of key concepts.
- **Recommendation posture** Currently not established from the provided evidence. The review has potential but requires substantial revision to provide a critical, well-organized, and evidence-based synthesis.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence quality
- **Claim pointer** The authors state that "RPA is always a phosphoprotein in the G2 phase" and that hyperphosphorylated isoforms after DSBs contain up to 13 or 14 phosphates.
- **Evidence pointer** Section 5, Figure 2
- **Concern** This claim is based on a single study using capillary IEF and phosphospecific antibodies. The authors present this as a general finding without discussing the limitations of the method, the specificity of the antibodies, or the possibility of cell-type-specific differences. The claim is overgeneralized and not supported by a broader body of evidence.
- **Why it matters** The central thesis of the review is that RPA phosphorylation is complex and functionally important. If the key quantitative claims are based on limited data, the review's foundation is weakened.
- **Resolution test** The authors should either provide a systematic review of multiple studies that support this claim or clearly state that this is a preliminary finding from one study and discuss its limitations.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Structural logic
- **Claim pointer** The review claims that the AlphaFold model of full-length RPA is useful for visualizing phosphorylation sites and understanding their potential impact on structure and interactions.
- **Evidence pointer** Section 2, Figure 1, Table 1
- **Concern** The AlphaFold model is presented as a reliable tool for this purpose, but the authors do not discuss the known limitations of AlphaFold for disordered regions, the variability of predictions, or the lack of experimental validation. The model is used to draw conclusions about the spatial arrangement of phosphorylation sites without acknowledging that these sites are in flexible regions.
- **Why it matters** The structural analysis is a key component of the review. If the model is overinterpreted, the conclusions about how phosphorylation affects RPA function may be misleading.
- **Resolution test** The authors should clearly state the limitations of AlphaFold predictions, compare the model to experimental structures where available, and avoid making definitive claims about the functional impact of phosphorylation based solely on the model.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence quality
- **Claim pointer** The authors state that "RPA phosphorylation significantly stabilized the RPA:RAD52 complex and regulates strand transfer" based on a single study.
- **Evidence pointer** Section 6, reference [93]
- **Concern** This is a strong mechanistic claim that is presented without critical evaluation of the experimental evidence. The authors do not discuss whether this finding has been replicated, whether it is specific to certain phosphorylation sites, or whether it applies to all cellular contexts.
- **Why it matters** This claim is used to support the therapeutic targeting of the phosphoRPA:RAD52 complex. If the evidence is not robust, the proposed therapeutic strategy is not well-founded.
- **Resolution test** The authors should provide a more detailed discussion of the study, including its methods and limitations, and should temper the claim if the evidence is preliminary.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Structural logic
- **Claim pointer** The review claims to cover "recent literature" on RPA phosphorylation, but the organization is repetitive and lacks a clear narrative.
- **Evidence pointer** Sections 3-6
- **Concern** The sections on function, interactions, and PTMs overlap significantly, with the same studies discussed multiple times. This makes the review feel disjointed and reduces its readability. The authors do not clearly distinguish between established findings, recent advances, and unresolved questions.
- **Why it matters** A well-organized review should guide the reader through the topic in a logical manner. The current structure obscures the key messages and makes it difficult to identify the novel contributions of the review.
- **Resolution test** The authors should restructure the review to have a clear thesis, with each section building on the previous one. They should avoid repetition and clearly state what is known, what is new, and what is unknown.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract
- **Evidence pointer** Abstract
- **Issue** The abstract is vague and does not clearly state the main conclusions or the unique contributions of the review.
- **Required correction** Revise the abstract to include a clear statement of the review's purpose, main findings, and future directions.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Readability
- **Affected element** Introduction
- **Evidence pointer** Section 1
- **Issue** The introduction includes excessive historical detail that is not essential for the review's focus.
- **Required correction** Condense the historical background and focus on the relevance of RPA phosphorylation to DSB repair.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Technical soundness
- **Affected element** Figure 2
- **Evidence pointer** Section 5, Figure 2
- **Issue** The figure is referenced but not adequately described in the text. The reader cannot fully understand the data presented without a detailed explanation.
- **Required correction** Provide a more detailed description of Figure 2, including the experimental conditions, the meaning of the peaks, and the antibodies used.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Section 6
- **Evidence pointer** Section 6
- **Issue** The future directions section is speculative and does not provide a clear research agenda.
- **Required correction** Provide specific, testable hypotheses and experimental approaches for future research.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Readability
- **Affected element** Section 7
- **Evidence pointer** Section 7
- **Issue** The conclusion is repetitive and does not synthesize the main points of the review.
- **Required correction** Rewrite the conclusion to summarize the key findings and their implications in a concise manner.

## Risk / unsupported claims
- The claim that "RPA is always a phosphoprotein in the G2 phase" is based on a single study and is presented as a general fact without discussion of limitations.
- The claim that "RPA phosphorylation significantly stabilized the RPA:RAD52 complex and regulates strand transfer" is based on a single study and is not critically evaluated.
- The AlphaFold model is presented as a reliable representation of full-length RPA without acknowledging its limitations for disordered regions.
- The statement that "the number of phosphorylation combinations is mind-boggling" is rhetorical and not supported by quantitative data.
- The therapeutic potential of targeting phosphoRPA:RAD52 is speculative and not grounded in experimental evidence.